ClinicalTrials.gg
WithdrawnNCT00676871Updated Sep 5, 2008

A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of MEDI-538 in Adults With B-Cell Chronic Lymphocytic Leukemia (CLL)

A Phase 1/2 interventional study of MEDI-538 and MEDI-538 in Chronic Lymphocytic Leukemia, sponsored by MedImmune LLC. Withdrawn. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2008-09-05.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 1/2, Interventional, and Treatment

Why this study was withdrawn
Replacing this trial with a new trial.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca — 6 open to participants now, 21 under way, 5 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · AstraZeneca.

Planned enrollment
21st of 29
30 · median 103
Started
2008
with 1 other
Phase 1/2
10 of 42
2 open now
Registered
4th of 42
by date

Among the 42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca, this one is the 21st largest by planned enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2008, is one of 10 in phase 1/2, and was the 4th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

6 of the 42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca, or all of them as a file.
02

Study summary

Phase 1:

  • Evaluate the safety and tolerability of MEDI-538 given by escalated doses with continuous IV infusion for 4 weeks in adult patients with CLL.
  • Determine the maximum tolerated dose (MTD) of MEDI-538 administered by continuous IV infusion for 4 weeks in this patient population
  • Describe the pharmacokinetics (PK) of MEDI-538
  • Describe the immunogenicity (IM) of MEDI-538
  • Determine the overall response, which is defined as follows: (1) conversion from PD/SD to PR/nPR/CR or conversion from PR to nPR/CR using standard NCI-WG criteria; or (2) conversion from MRD positivity to MRD negativity using 4-color flow cytometry; and
  • Describe any antitumor activity (ie, time to response and duration of response) of MEDI-538 in this patient population.

Phase 2:

  • To determine the overall response in adult patients with CLL who have residual disease following previous therapy for CLL.
  • Describe the safety,PK,and IM of MEDI-538
  • Determine the time to MRD relapse
  • Determine the antitumor activity (ie, time to response, duration of response,and time to progression [TTP])of MEDI-538 in this patient population.
Read the detailed description

Phase 1:

  • Evaluate the safety and tolerability of MEDI-538 at doses of 5, 10, 15, 30, 45, or 60 mg/m2/24h by continuous IV infusion for 4 weeks in adult patients with CLL who have measurable disease following previous therapy for CLL. Patients with measurable disease include patients who demonstrated PD, SD, or PR following previous therapy for CLL; and
  • Determine the maximum tolerated dose (MTD) of MEDI-538 administered by continuous IV infusion for 4 weeks in this patient population;
  • Describe the pharmacokinetics (PK) of MEDI-538
  • Describe the immunogenicity (IM) of MEDI-538
  • Determine the overall response, which is defined as follows: (1) conversion from PD/SD to PR/nPR/CR or conversion from PR to nPR/CR using standard NCI-WG criteria; or (2) conversion from MRD positivity to MRD negativity using 4-color flow cytometry; and
  • Describe any antitumor activity (ie, time to response and duration of response) of MEDI-538 in this patient population.

Phase 2:

  • Determine the overall response in adult patients with CLL who have residual disease following previous therapy for CLL.
  • Describe the safety of MEDI-538
  • Describe the PK of MEDI-538
  • Describe the IM of MEDI-538
  • Determine the time to MRD relapse
  • Determine the antitumor activity (ie, time to response, duration of response, and time to progression [TTP]) of MEDI-538 in this patient population.
03

Conditions studied

  • Chronic Lymphocytic Leukemia
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult men or women at least 18 years of age;
  • Written and Heath Insurance Portability and Accountability Act (HIPAA) authorization (applies to covered entities in the USA only) obtained from the patient prior to performing any study-related procedures, including screening visits;
  • Previous confirmation of B-cell CLL with a characteristic immunophenotype by flow cytometry;
  • MRD positivity, determined by 4-color flow cytometry of bone marrow or peripheral blood in all patients following previous therapy for CLL;
  • Measurable and/or residual disease following previous therapy for CLL as follows:

    1. , as determined by NCI-WG criteria, following standard or salvage therapy; this includes patients with PD, SD, or PR (Phase 1 only);
    2. Residual disease as determined by measurable disease (ie, PD, SD, or PR) or by MRD positivity, determined by 4-color flow cytometry of bone marrow and/or peripheral blood in patients with CR or nPR (Phase 2 only);
  • Time from completing last therapy for CLL is ≥ 3 months but ≤ 1 year;
  • (ECOG) performance status ≤ 2;
  • Presence of live-in companion (relative or friend) who agrees to NOT leave the patient unattended for > 8 hours per day;
  • Patient agrees to refrain from engaging in hazardous occupations or activities requiring complete mental alertness such as operating machinery or driving a motor vehicle;
  • Females, unless surgically sterile or at least 1 year , must use an effective method of avoiding pregnancy (including oral, transdermal, or implanted , intrauterine device, female condom with spermicide, diaphragm with spermicide, cervical cap, abstinence, use of a condom with spermicide by the sexual partner or sterile sexual partner) for 21 days prior to the first dose of MEDI-538, and must agree to continue using such precautions through 3 months after the last dose of MEDI-538. Cessation of birth control after this point should be discussed with a responsible physician. Males, unless surgically sterile, must likewise use an effective method of birth control (condom with spermicide) and must agree to continue using such precautions through 3 months after the last dose of MEDI-538;
  • ≥ 10.0 g/dL and > 75.0 x 109/L;
  • Total ≤ 1.5 x ; (AST), alanine transaminase (ALT), amylase and lipase ≤ 2 x ULN;
  • Serum creatinine ≤ 2 x ULN and ≥ 50 mL/min;
  • (ANC) > 1.0 × 109/L; and
  • For patients who have received previous treatment with alemtuzumab, must be > 200 cells/μL with a negative status for cytomegalovirus (CMV) antigen.

Exclusion criteria

Exclusion Criteria:

  • Receipt of MEDI-538 in any previous clinical study;
  • History of allergy or reaction to any component of the MEDI-538 formulation;
  • History of other than CLL within 5 years prior to study entry, with the exception of basal cell carcinoma of the skin or carcinoma in situ of the cervix successfully treated with curative therapy;
  • Fludarabine- CLL, defined as failure to achieve a PR or CR/nPR to at least one fludarabine-containing regimen, disease progression while on fludarabine treatment, or disease progression in responders within 6 months of last dose of fludarabine;
  • Known or suspected CNS involvement;
  • Clinical history of significant CNS pathology, eg, uncontrolled headaches, multiple occurrences of confusion, dementia, multiple previous infarcts, or major brain surgery;
  • Active infection or known bacteremia. Patients with documented evidence of culture positive sepsis or active infection requiring IV antibiotic therapy must complete a full course of antibiotic treatment with no clinical or laboratory evidence of bacterial infection at least 2 weeks prior to starting therapy with MEDI-538.
  • Vaccination (either preventive or therapeutic for infectious disease or cancer) within 2 weeks prior to initiation of MEDI-538;
  • Infection with (HIV-1 or HIV-2), chronic infection with or C, or acute infection with hepatitis A;
  • History of serious, chronic disease, eg, rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis;
  • Elective surgery planned during the study period through 30 days after discontinuation of MEDI-538;
  • stem cell transplantation within 26 weeks prior to study entry;
  • Allogenic stem cell transplantation or any other solid organ transplant;
  • Regular dose of systemic during the 4 weeks prior to initiation of MEDI-538 or anticipated need of corticosteroids exceeding prednisone 20 mg/day or equivalent during the trial, or any other systemic therapy within 4 weeks prior to study entry;
  • Any to chronic anticoagulation with low-molecular weight heparin (LMWH);
  • Inability for safe placement and prolonged use (at least 4 weeks) of a central venous catheter;
  • Contraindication to any of the protocol-specified concomitant medications (methylprednisolone, antacids, or antihistamines) during this study;
  • Presence of known human anti-murine antibodies or to immunoglobulins;
  • Pregnancy (females of must have a negative urine pregnancy test on the day of the first dose of MEDI-538, prior to dosing) or nursing;
  • Evidence of any uncontrolled systemic disease (other than CLL), including autoimmune hemolytic anemia;
  • Any finding upon physical examination or history of any disease or behavior that, in the opinion of the investigator or medical monitor, may compromise the safety of the patient in the study or confound the analysis of the study; or
  • Inability to meet social environment requirements for outpatient therapy (see Section 3.3.4.2).
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    1

    MEDI-538

    Drug: MEDI-538

  • Experimental
    2

    MEDI-538

    Drug: MEDI-538

  • Experimental
    3

    MEDI-538

    Drug: MEDI-538

  • Experimental
    4

    MEDI-538

    Drug: MEDI-538

  • Experimental
    5

    MEDI-538

    Drug: MEDI-538

  • Experimental
    6

    MEDI-538

    Drug: MEDI-538

  • Experimental
    7

    MEDI-538

    Drug: MEDI-538

Interventions

  • Dose one of MEDI 538 as a continuous IV infusion - dose level is 5 mg/m2/24h (Phase 1)

  • Dose two of MEDI 538 as a continuous IV infusion - dose level is 10 mg/m2/24h (Phase 1)

  • Dose three of MEDI 538 as a continuous IV infusion-dose level is 15mg/m2/24h (Phase 1)

  • Dose four of MEDI 538 as a continuous IV infusion - dose level is 30 mg/m2/24h(Phase 1)

  • Dose five of MEDI 538 as a continuous IV infusion - dose level is 45 mg/m2/24h (Phase 1)

  • Dose six of MEDI 538 as a continuous IV infusion - dose level is 60 mg/m2/24h (Phase 1)

  • Phase 2 part of the study, 20 to 60 patients will be treated with MEDI 538 as a continuous IV infusion through a central line catheter. The dose of MEDI-538 will be determined in the Phase 1 part of the study.

06

What researchers measure

Primary outcomes

  1. The primary outcome of the Phase 1 part of the study are to evaluate the safety, tolerability, and MTD of MEDI-538 by continuous IV infusion for 4 weeks in adult patients with CLL who have measurable disease following previous therapy for CLL.

    Time frame: 30 days after patient's final dose of study drug

  2. The primary objective of the Phase 2 part of the study is to determine the overall response in adult patients with CLL who have residual disease following previous therapy for CLL.

    Time frame: 30 days after patient's final dose of study drug

Secondary outcomes

  1. The secondary outcome of the Phase 1 part of the study include measurement of the PK, IM, and antitumor activity of MEDI-538 in this patient population.

    Time frame: 30 days after patient's final dose of study drug

  2. The secondary objectives of the Phase 2 part of the study include safety, measurement of the PK, IM, and antitumor activity of MEDI-538 in this patient population.

    Time frame: 30 days after patient's final dose of study drug

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Mar 2010 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2008
First posted
May 13, 2008
Start
Jun 2008
Primary completionEst.
Mar 2010
CompletionEst.
Jun 2011
Last update
Sep 5, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00676871
Lead sponsor
MedImmune LLC
First posted
May 13, 2008
Start date
Jun 2008
Primary completion
Mar 2010 (estimated)
Completion
Jun 2011 (estimated)
Last update
Sep 5, 2008

Study contacts

Karen Kaucic, M.D.
study director · MedImmune LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Blinatumomab

Start the discussion